Trimodality Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer

Restricted access

Potentially curative treatments for patients with muscle-invasive bladder cancer (MIBC) are underused, especially in the elderly. Trimodality bladder preservation therapy, which includes a maximally safe transurethral resection of the bladder tumor, followed by concurrent chemoradiation, fulfills this currently unmet need. In multiple prospective clinical trials and large institutional series, trimodality therapy has demonstrated excellent 5-year overall survival rates of 48% to 65%, comparable to those reported in cystectomy studies. Approximately 75% to 80% of long-term survivors maintain their native bladders, which tend to function well and allow patients to maintain excellent quality of life. Salvage cystectomy for patients who develop a local invasive recurrence can be performed with acceptable operative complication rates, and results in excellent long-term disease control and survival outcomes. For patients with MIBC who are noncystectomy candidates, or select patients who are motivated to keep their native bladders, trimodality bladder preservation therapy is recognized by the International Consultation on Urological Diseases-European Association of Urology and the NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer as an effective alternative to radical cystectomy, and should be considered. In the future, biomarkers may allow improved selection of patients for whom trimodality bladder preservation therapy is most likely to succeed.

Correspondence: Ronald C. Chen, MD, MPH, Department of Radiation Oncology, University of North Carolina at Chapel Hill, 101 Manning Drive, CB 7512, Chapel Hill, NC 27599-7512. E-mail: ronald_chen@med.unc.edu
  • 1.

    SiegelRNaishadhamDJemalA. Cancer statistics, 2012. CA Cancer J Clin2012;62:1029.

  • 2.

    GrayPFedewaSShipleyW. Use of potentially curative therapies for muscle-invasive bladder cancer in the united states: results from the National Cancer Data Base. Eur Urol2013;63:823829.

    • Search Google Scholar
    • Export Citation
  • 3.

    LundLJacobsenJClarkP. Impact of comorbidity on survival of invasive bladder cancer patients, 1996-2007: a Danish population-based cohort study. Urology2010;75:393398.

    • Search Google Scholar
    • Export Citation
  • 4.

    MegwaluIIVlahiotisARadwanM. Prognostic impact of comorbidity in patients with bladder cancer. Eur Urol2008;53:581589.

  • 5.

    ClarkPEAgarwalNEisenbergerMA. NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer. Version 12013. Available at: NCCN.org. Accessed July 10 2013.

    • Search Google Scholar
    • Export Citation
  • 6.

    GakisGEfstathiouJLernerSP. ICUD-EAU International Consultation on Bladder Cancer 2012: radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder. Eur Urol2013;63:4557.

    • Search Google Scholar
    • Export Citation
  • 7.

    FroehnerMBrausiMAHerrHW. Complications following radical cystectomy for bladder cancer in the elderly. Eur Urol2009;56:443454.

  • 8.

    DonatSMShabsighASavageC. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical cystectomy: a high-volume tertiary cancer center experience. Eur Urol2009;55:177185.

    • Search Google Scholar
    • Export Citation
  • 9.

    LibermanDLughezzaniGSunM. Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder. Urology2011;77:660666.

    • Search Google Scholar
    • Export Citation
  • 10.

    KaufmanDSShipleyWUGriffinPP. Selective bladder preservation by combination treatment of invasive bladder cancer. N Engl J Med1993;329:13771382.

    • Search Google Scholar
    • Export Citation
  • 11.

    MakRHuntDShipleyW. Long-term outcomes in patients with muscle-invasive bladder cancer after bladder-preserving combined-modality therapy: a pooled analysis of RTOG 8802, 8903, 9506, 9706, 9906, and 0233 [abstract]. J Clin Oncol2012;30(Suppl 5):Abstract 264.

    • Search Google Scholar
    • Export Citation
  • 12.

    EfstathiouJASpiegelDYShipleyWU. Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: the MGH experience. Eur Urol2012;61:705711.

    • Search Google Scholar
    • Export Citation
  • 13.

    RödelCGrabenbauerGGKühnR. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol2002;20:30613071.

    • Search Google Scholar
    • Export Citation
  • 14.

    PerdonàSAutorinoRDamianoR. Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer: a multi-institutional, long-term experience. Cancer2008;112:7583.

    • Search Google Scholar
    • Export Citation
  • 15.

    JamesNDHussainSAHallE. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med2012;366:14771488.

  • 16.

    ShipleyWUWinterKAKaufmanDS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol1998;16:35763583.

    • Search Google Scholar
    • Export Citation
  • 17.

    EfstathiouJAShipleyWU. Words of wisdom. Re: radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. Eur Urol2013;63:181182.

    • Search Google Scholar
    • Export Citation
  • 18.

    HussainSAMoffittDDGlaholmJG. A phase I-II study of synchronous chemoradiotherapy for poor prognosis locally advanced bladder cancer. Ann Oncol2001;12:929935.

    • Search Google Scholar
    • Export Citation
  • 19.

    KentESandlerHMontieJ. Combined-modality therapy with gemcitabine and radiotherapy as a bladder preservation strategy: results of a phase I trial. J Clin Oncol2004;22:25402545.

    • Search Google Scholar
    • Export Citation
  • 20.

    ChoudhuryASwindellRLogueJP. Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscle-invasive bladder cancer. J Clin Oncol2011;29:733738.

    • Search Google Scholar
    • Export Citation
  • 21.

    GrossmanHBNataleRBTangenCM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med2003;349:859866.

    • Search Google Scholar
    • Export Citation
  • 22.

    ZehnderPStuderUESkinnerEC. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study. J Urol2011;186:12611268.

    • Search Google Scholar
    • Export Citation
  • 23.

    GrayPJFedewaSAShipleyWU. Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: associations with clinical variables and survival [abstract]. J Clin Oncol2013;31(Suppl 6):Abstract 248.

    • Search Google Scholar
    • Export Citation
  • 24.

    MalmströmPURintalaEWahlqvistR. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol1996;155:19031906.

    • Search Google Scholar
    • Export Citation
  • 25.

    SherifARintalaEMestadO. Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer—Nordic Cystectomy Trial 2. Scand J Urol Nephrol2002;36:419425.

    • Search Google Scholar
    • Export Citation
  • 26.

    KaufmanDSWinterKAShipleyWU. The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist2000;5:471476.

    • Search Google Scholar
    • Export Citation
  • 27.

    KaufmanDSWinterKAShipleyWU. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twice-daily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology2009;73:833837.

    • Search Google Scholar
    • Export Citation
  • 28.

    HaganMPWinterKAKaufmanDS. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy. Int J Radiat Oncol Biol Phys2003;57:665672.

    • Search Google Scholar
    • Export Citation
  • 29.

    EfstathiouJABaeKShipleyWU. Late pelvic toxicity after bladder-sparing therapy in patients with invasive bladder cancer: RTOG 89-03, 95-06, 97-06, 99-06. J Clin Oncol2009;27:40554061.

    • Search Google Scholar
    • Export Citation
  • 30.

    ZapateroAGarcía-VicenteFMartín de VidalesC. Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?Int J Radiat Oncol Biol Phys2011;81:12791285.

    • Search Google Scholar
    • Export Citation
  • 31.

    LagrangeJLBascoul-MolleviCGeoffroisL. Quality of life assessment after concurrent chemoradiation for invasive bladder cancer: results of a multicenter prospective study (GETUG 97-015). Int J Radiat Oncol Biol Phys2011;79:172178.

    • Search Google Scholar
    • Export Citation
  • 32.

    ZietmanALSaccoDSkowronskiU. Organ conservation in invasive bladder cancer by transurethral resection, chemotherapy and radiation: results of a urodynamic and quality of life study on long-term survivors. J Urol2003;170:17721776.

    • Search Google Scholar
    • Export Citation
  • 33.

    HoussetMMaulardCChretienY. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol1993;11:21502157.

    • Search Google Scholar
    • Export Citation
  • 34.

    EswaraJREfstathiouJAHeneyNM. Complications and long-term results of salvage cystectomy after failed bladder sparing therapy for muscle invasive bladder cancer. J Urol2012;187:463468.

    • Search Google Scholar
    • Export Citation
  • 35.

    TesterWCaplanRHeaneyJ. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol1996;14:119126.

    • Search Google Scholar
    • Export Citation
  • 36.

    ZapateroAMartin de VidalesCArellanoR. Updated results of bladder-sparing trimodality approach for invasive bladder cancer. Urol Oncol2010;28:368374.

    • Search Google Scholar
    • Export Citation
  • 37.

    FungCYShipleyWUYoungRH. Prognostic factors in invasive bladder carcinoma in a prospective trial of preoperative adjuvant chemotherapy and radiotherapy. J Clin Oncol1991;9:15331542.

    • Search Google Scholar
    • Export Citation
  • 38.

    ChoudhuryANelsonLDTeoMT. MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res2010;70:70177026.

    • Search Google Scholar
    • Export Citation
  • 39.

    LaurbergJRBrems-EskildsenASNordentoftI. Expression of TIP60 (tat-interactive protein) and MRE11 (meiotic recombination 11 homolog) predict treatment-specific outcome of localised invasive bladder cancer. BJU Int2012;110:E12281236.

    • Search Google Scholar
    • Export Citation
  • 40.

    MitinTHuntDShipleyWU. Transurethral surgery and twice-daily radiation plus paclitaxel-cisplatin or fluorouracil-cisplatin with selective bladder preservation and adjuvant chemotherapy for patients with muscle invasive bladder cancer (RTOG 0233): a randomised multicentre phase 2 trial. Lancet Oncolin press.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 295 295 37
PDF Downloads 38 38 7
EPUB Downloads 0 0 0